Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

21. Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta-analysis. (Full text)

Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta-analysis. A substantial proportion of atrial fibrillation patients initiating direct oral anticoagulants (DOAC) are vitamin K antagonists (VKA)-experienced, for example switchers from VKA to DOAC. With this study, we aimed to summarize available evidence on the effectiveness and safety of DOAC vs VKA in real-life VKA-experienced atrial (...) -1.94, I2  = 30%]), but a decreased risk of intracranial bleeding (pooled aHR 0.45 [95% CI 0.32-0.64, I2  = 0%]). In conclusion, the use of dabigatran in prior VKA users in clinical practice was associated with a slightly increased risk of arterial thromboembolism and gastrointestinal bleeding, but a decreased risk of intracranial bleeding. Importantly, observational studies of real-life VKA-experienced oral anticoagulant users may be confounded by the reason for switching.© 2019 The Authors. Basic

2020 Basic & clinical pharmacology & toxicology PubMed abstract

22. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. (Full text)

Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. Our study aims to perform a meta-analysis of benefits and risks associated with the use of non-vitamin K oral anticoagulants (NOAC) versus vitamin K antagonists (VKA) in patients with a percutaneous coronary intervention (PCI) with a particular focus on the combination type

2020 Journal of clinical medicine PubMed abstract

23. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. (Abstract)

Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. Direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). Concomitant antiplatelet therapy may potentiate the antithrombotic effects of DOACs.We evaluated the impact of concomitant antiplatelet therapy on the efficacy and safety of DOACs.MEDLINE (...) anticoagulant (odds ratio [OR] 1.17; 95% confidence interval [CI], 0.92-1.48), with DOACs (OR 1.21; 95% CI, 0.86-1.71), or VKAs alone (OR 1.16; 95% CI, 0.77-1.73). Compared with no antiplatelet therapy, concomitant antiplatelet therapy was associated with a higher risk of major bleeding in patients with any oral anticoagulant (OR 1.79; 95% CI, 1.22-2.63), DOACs (OR 1.89; 95% CI, 1.04-3.44), or VKAs (OR 1.73; 95% CI, 1.16-2.59). In patients receiving concomitant antiplatelet therapy, there were

2020 Journal of thrombosis and haemostasis : JTH

24. A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation. (Full text)

A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation. While a plethora of systematic reviews have provided evidence of efficacy, effectiveness and safety of direct-acting oral anticoagulants (DOACs) in the management of nonvalvular atrial fibrillation, there has been little emphasis on clinicians' perspectives. This systematic review aimed to critically appraise, synthesize and present the available (...) Ratio and likely to miss appointments. There were, however, concerns relating to management of over-anticoagulation and experiences of observed bleeding rates.There is a limited evidence base of clinicians' perspectives of DOACs, necessitating further research, particularly given the trajectory of increased use worldwide.© 2018 The British Pharmacological Society.

2020 British journal of clinical pharmacology PubMed abstract

25. Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use. (Full text)

Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use. To obtain precise estimates of age, haematoma volume, secondary haematoma expansion (HE) and mortality for patients with intracerebral haemorrhage (ICH) taking oral anticoagulants [Vitamin K antagonists (VKA-ICH) or non-Vitamin K antagonist oral anticoagulants (NOAC-ICH)] and those not taking oral anticoagulants (non-OAC ICH) at ICH symptom onset.We conducted

2020 Journal of neurology PubMed abstract

26. Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. (Full text)

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. Patients receiving vitamin K antagonists (VKAs) with an international normalized ratio (INR) between 4.5 and 10 are at increased risk of bleeding. We systematically reviewed the literature to evaluate the effectiveness and safety of administering vitamin K in patients receiving VKA therapy with INR between 4.5 and 10 and without bleeding. Medline, Embase, and Cochrane databases were

2020 Blood advances PubMed abstract

27. The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: A systematic review. (Abstract)

The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: A systematic review. Use of non-vitamin K antagonist oral anticoagulants (NOACs), including dabigatran etexilate, rivaroxaban, apixaban, edoxaban or betrixaban provides a safe and convenient alternative to the traditional anticoagulation with vitamin K antagonists or heparin derivatives. Many patients receiving long-term seizure prophylaxis with antiepileptic drugs (AEDs) may require anticoagulation (...) and consequent thrombotic events. Only one article, a case report, was identified that focused on interactions between the second generation AED and a NOAC. At the present time, the limited evidence suggests that enzyme-inducing or inhibiting AEDs reduce the effectiveness of anticoagulation produced by several NOACs. This information may help providers anticipate possible interactions and guide therapy appropriately.Copyright © 2020 Elsevier B.V. All rights reserved.

2020 Epilepsy research

28. Response to "Letter to the Editor concerning: 'A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants'". (Abstract)

Response to "Letter to the Editor concerning: 'A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants'". 31898985 2020 04 13 1874-1754 306 2020 May 01 International journal of cardiology Int. J. Cardiol. Response to "Letter to the Editor concerning: 'A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison (...) of efficacy and safety following treatment with direct oral anticoagulants'". 101 S0167-5273(19)35800-0 10.1016/j.ijcard.2019.11.141 Cohen A T AT Guy's and St. Thomas' Hospitals, King's College, London, UK. Hill N R NR Bristol-Myers Squibb Company, Lawrenceville, NJ, USA. Luo X X Pfizer, Inc., New York, NY, USA. Masseria C C Pfizer, Inc., New York, NY, USA. Abariga S A SA Evidera, Inc., Waltham, MA, USA. Ashaye A O AO Evidera, Inc., Waltham, MA, USA. Electronic address: ajibade_ashaye@yahoo.com. eng

2020 International journal of cardiology

29. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. (Full text)

A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Nephrotic syndrome is associated with an increased risk of venous and arterial thromboembolism, which can be as high as 40% depending on the severity and underlying cause of nephrotic syndrome. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend prophylactic anticoagulation only in idiopathic membranous nephropathy but acknowledge that existing data are limited and of low quality (...) . There is a need for better identification of vulnerable patients in order to balance the risks of anticoagulation.We undertook a systematic search of the topic in MEDLINE, EMBASE and COCHRANE databases, for relevant articles between 1990 and 2019.A total of 2381 articles were screened, with 51 full-text articles reviewed. In all, 28 articles were included in the final review.We discuss the key questions of whom to anticoagulate, when to anticoagulate, and how to prophylactically anticoagulate adults

2020 Kidney international reports PubMed abstract

30. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. (Abstract)

Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. Cerebral venous thrombosis (CVT) causes significant disability and mortality. Current guidelines for CVT management support the initial use of unfractionated heparin or low molecular weight heparin followed by longer-term oral vitamin K antagonist (VKA). There has been increasing, albeit limited, evidence for the use of direct oral anticoagulants (DOAC) as an alternative

2020 Journal of thrombosis and thrombolysis

31. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis. (Abstract)

Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis. Systemic anticoagulants are widely prescribed for prevention and treatment of thromboembolism, but are commonly complicated by gastrointestinal bleeding (GIB). Limited data exist on the management of anticoagulation after hospitalization for GIB and the subsequent risks of recurrent GIB (...) , thromboembolism, and mortality.We performed a systematic review and meta-analysis of studies to determine risk of recurrent GIB, thromboembolism, and mortality after resuming anticoagulation following GIB. PubMed, EMBASE, and Scopus were searched for randomized controlled trials and cohort studies in patients with atrial fibrillation, venous thromboembolism, or valvular heart disease who received long-term warfarin or direct oral anticoagulants before experiencing GIB. Studies were included if data were

2020 Digestive diseases and sciences

32. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. (Full text)

Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. Medications cannot exert their effect if not taken as prescribed by patients. Our objective was to summarise the observational evidence on adherence to oral anticoagulants (OACs) among patients with atrial fibrillation (AF).In March 2019, we systematically searched PubMed/Medline, Embase, CINAHL and PsycINFO (from inception) for observational studies

2020 BMJ open PubMed abstract

33. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. (Full text)

Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. 31948304 2020 04 10 1473-2300 48 1 2020 Jan The Journal of international medical research J. Int. Med. Res. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. 300060519896919 10.1177/0300060519896919 Zhang Mengying M https://orcid.org/0000-0001-7492-3666 Department of Respiratory Medicine, National Key Clinical Specialty, Xiangya Hospital, Central South University, Changsha (...) , Hunan, China. Wu Shuxie S Reproductive Medicine Center, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hu Chengping C Department of Respiratory Medicine, National Key Clinical Specialty, Xiangya Hospital, Central South University, Changsha, Hunan, China. eng Journal Article England J Int Med Res 0346411 0300-0605 IM Lung cancer anticoagulation prognosis risk factor thromboprophylaxis thrombosis 2020 1 18 6 0 2020 1 18 6 0 2020 1 18 6 0 ppublish 31948304 10.1177/0300060519896919

2020 The Journal of international medical research PubMed abstract

34. Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. (Abstract)

Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. The optimal antithrombotic strategy for patients with a long-term indication for anticoagulation and acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) remains controversial. This meta-analysis aims to compare randomised trials' outcomes of these patients, focussing on dual versus triple antithrombotic and non vitamin K oral (...) anticoagulants (NOACs) versus vitamin K oral anticoagulants regimens.Medline, Embase and Cochrane databases were searched from January 1980 to March 2019 yielding 309 articles, and after careful screening, five randomized trials totalling 10 643 patients were included for analysis.Dual antithrombotic regimens were associated with significantly less thrombolysis in myocardial infarction (TIMI) major and minor bleeding [odds ratio (OR) 0.53, 95% confidence interval (CI) 0.40-0.71], with no significant

2020 Coronary artery disease

35. Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis. (Full text)

Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis. Atrial fibrillation (AF) and coronary artery disease (CAD) are commonly associated. Cotreatment with multiple antithrombotic agents can increase the risk of bleeding. We sought to evaluate patient-centered outcomes in patients with AF on double therapy with direct oral anticoagulants (DOACs

2020 Journal of arrhythmia PubMed abstract

36. Editorial to the "safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation: A systematic revie and meta-analysis". (Full text)

Editorial to the "safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation: A systematic revie and meta-analysis". 32256874 2020 04 09 1880-4276 36 2 2020 Apr Journal of arrhythmia J Arrhythm Editorial to the "safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation (...) : A systematic revie and meta-analysis". 280-281 10.1002/joa3.12317 Okumura Yasuo Y https://orcid.org/0000-0002-2960-4241 Division of Cardiology Department of Medicine Nihon University School of Medicine Tokyo Japan. Nagashima Koichi K Division of Cardiology Department of Medicine Nihon University School of Medicine Tokyo Japan. eng Editorial 2020 02 17 Japan J Arrhythm 101263026 1880-4276 atrial fibrillation direct oral anticoagulants dual therapy percutaneous coronary intervention 2019 12 18 2019 12 23

2020 Journal of arrhythmia PubMed abstract

37. Antiplatelet and Anticoagulant Use in Randomised Trials of Patients Undergoing Endovascular Intervention for Peripheral Arterial Disease: Systematic Review and Narrative Synthesis. (Abstract)

Antiplatelet and Anticoagulant Use in Randomised Trials of Patients Undergoing Endovascular Intervention for Peripheral Arterial Disease: Systematic Review and Narrative Synthesis. Randomised trials of new devices for peripheral arterial endovascular intervention are published regularly. The evidence for which antiplatelet and/or anticoagulant (antithrombotic) therapy to use after an intervention is lacking. The aim of this systematic review was to examine the antithrombotic regimens

2020 European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

38. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis. (Full text)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis. There are few head-to-head trials directly comparing non-vitamin K antagonist oral anticoagulants (NOACs) against one other. A network meta-analysis (NMA) was performed to examine the indirect comparisons among NOACs in Asians with nonvalvular atrial fibrillation (NVAF). STATA 15.0 and ADDIS 1.16.8 softwares were used to perform the statistical analysis

2020 Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis PubMed abstract

39. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease. (Full text)

Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease. The efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) with coronary or peripheral artery disease (CAD or PAD) remain largely unresolved. We, therefore, conducted a meta-analysis to explore the effect of NOACs compared with warfarin in these populations.We systematically searched the Cochrane Library

2020 International heart journal PubMed abstract

40. Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling me (Full text)

Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling me There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark (...) trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients.We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies

2020 Medicine PubMed abstract